<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136262</url>
  </required_header>
  <id_info>
    <org_study_id>2018YFC1705204</org_study_id>
    <nct_id>NCT04136262</nct_id>
  </id_info>
  <brief_title>Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis</brief_title>
  <official_title>Tripterygium Wilfordii Hook F and Methotrexate for Postmenopausal Women With Rheumatoid Arthritis: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, randomized, double-blinded, controlled trial with two parallel
      arms. The aim of the study is to evaluate whether Tripterygium wilfordii Hook F combined with
      methotrexate (MTX) might be better than MTX alone for postmenopausal women with active
      rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy and safety of Tripterygium wilfordii Hook F (TwHF) and methotrexate
      (MTX) for postmenopausal women with active rheumatoid arthritis (RA), a multicenter,
      randomized controlled trial will be conducted. Three hundred postmenopausal women with active
      RA will be randomly allocated (1:1) to treatment with TwHF 20mg thrice daily and MTX 10 mg
      once a week for 24 weeks, or MTX plus dummy TwHF. The primary outcome is the percentage of
      participants with American College of Rheumatology 20% at week 24.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of ACR20</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 20% (ACR20)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of ACR50</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 50% (ACR 50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of ACR70</measure>
    <time_frame>week 24</time_frame>
    <description>Percentage of Participants With American College of Rheumatology 70% (ACR 70)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RAMRIS score</measure>
    <time_frame>week 24</time_frame>
    <description>To explore the structural efficacy of Tripterygium wilfordii Hook F (TwHF) on synovitis, osteitis, and joint erosions as measured by MRI in postmenopausal women with active RA using the change in the RAMRIS score from Baseline to Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean 24-week Change in Disease Activity Score Based on 28-Joint Count (DAS28)</measure>
    <time_frame>week 24</time_frame>
    <description>Average difference between 24-week and Baseline DAS28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Modified Total Sharp X-Ray Score at Week 24</measure>
    <time_frame>week 24</time_frame>
    <description>Modified Total Sharp Score (mTSS) is a measure of joint health, used in evaluation of inhibition of radiographic progression of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Reported Outcomes (PRO)</measure>
    <time_frame>week 24</time_frame>
    <description>Patient-Reported Outcomes Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TwHF (dummy) plus MTX</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks. Oral methotrexate 10 mg per week for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tripterygium wilfordii Hook F (TwHF)</intervention_name>
    <description>Oral Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.</description>
    <arm_group_label>Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)</arm_group_label>
    <other_name>DND Pharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral methotrexate 10 mg per week for 24 weeks.</description>
    <arm_group_label>Tripterygium wilfordii Hook F (TwHF) plus methotrexate (MTX)</arm_group_label>
    <arm_group_label>TwHF (dummy) plus MTX</arm_group_label>
    <other_name>XINYI Pharm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dummy Tripterygium wilfordii Hook F (TwHF)</intervention_name>
    <description>Oral dummy Tripterygium wilfordii Hook F 20mg thrice daily for 24 weeks.</description>
    <arm_group_label>TwHF (dummy) plus MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. postmenopausal women, postmenopausal defined as 12 months of spontaneous amenorrhea or
             6 months of spontaneous amenorrhea with serum FSH levels &gt; 40 mIU/ml or 6 weeks
             postsurgical bilateral oophorectomy with or without hysterectomy;

          2. diagnosed with RA as determined by meeting the 2010 ACR/EULAR classification criteria
             and having had RA for at least 6 weeks;

          3. active disease at the time of enrollment as indicated by 28-joint Disease Activity
             Score (DAS28) greater than 3.2;

          4. no prior exposure to oral glucocorticoids at a daily dose greater than 10 mg or to any
             biologic agents.

        Exclusion Criteria:

          1. RA combined with other autoimmune disease, such as adjuvant arthritis, lupus
             arthritis, or osteoarthritis;

          2. RA combined with abnormal liver and kidney function;

          3. severe chronic or acute disease interfering with attendance for therapy;

          4. patients who had received DMARDs or biological therapy within one months before
             participating in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quan Jiang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guang' anmen hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quan Jiang, M.D</last_name>
    <phone>+8613901081632</phone>
    <phone_ext>0</phone_ext>
    <email>doctorjq@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guang'anmen Hospital, China Academy of Chinese Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quan Jiang, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>December 28, 2019</last_update_submitted>
  <last_update_submitted_qc>December 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Quan Jiang</investigator_full_name>
    <investigator_title>Guang'anmen Hospital</investigator_title>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>Tripterygium wilfordii Hook F</keyword>
  <keyword>methotrexate</keyword>
  <keyword>postmenopausal women</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

